nodes	percent_of_prediction	percent_of_DWPC	metapath
Amantadine—SIGMAR1—Progesterone—uterine cancer	0.322	0.43	CbGbCtD
Amantadine—SLC22A2—Progesterone—uterine cancer	0.167	0.224	CbGbCtD
Amantadine—SLC22A1—Progesterone—uterine cancer	0.145	0.194	CbGbCtD
Amantadine—ABCB1—Progesterone—uterine cancer	0.0446	0.0596	CbGbCtD
Amantadine—ABCB1—Dactinomycin—uterine cancer	0.0353	0.0473	CbGbCtD
Amantadine—ABCB1—Etoposide—uterine cancer	0.0199	0.0267	CbGbCtD
Amantadine—ABCB1—Doxorubicin—uterine cancer	0.0136	0.0182	CbGbCtD
Amantadine—SIGMAR1—Levonorgestrel—Progesterone—uterine cancer	0.00346	1	CbGdCrCtD
Amantadine—DDC—renal system—uterine cancer	0.00145	0.0587	CbGeAlD
Amantadine—SLC22A2—renal system—uterine cancer	0.0012	0.0484	CbGeAlD
Amantadine—DDC—female reproductive system—uterine cancer	0.00116	0.047	CbGeAlD
Amantadine—GRIN2A—vagina—uterine cancer	0.00113	0.0455	CbGeAlD
Amantadine—SIGMAR1—myometrium—uterine cancer	0.00107	0.0433	CbGeAlD
Amantadine—MAOB—myometrium—uterine cancer	0.00103	0.0415	CbGeAlD
Amantadine—SLC22A1—renal system—uterine cancer	0.000845	0.0342	CbGeAlD
Amantadine—SIGMAR1—uterine cervix—uterine cancer	0.000835	0.0337	CbGeAlD
Amantadine—SIGMAR1—smooth muscle tissue—uterine cancer	0.000811	0.0328	CbGeAlD
Amantadine—MAOB—uterine cervix—uterine cancer	0.000799	0.0323	CbGeAlD
Amantadine—SIGMAR1—decidua—uterine cancer	0.000795	0.0321	CbGeAlD
Amantadine—MAOB—decidua—uterine cancer	0.000761	0.0308	CbGeAlD
Amantadine—SIGMAR1—endometrium—uterine cancer	0.000755	0.0305	CbGeAlD
Amantadine—MAOB—renal system—uterine cancer	0.000748	0.0302	CbGeAlD
Amantadine—SIGMAR1—mammalian vulva—uterine cancer	0.00073	0.0295	CbGeAlD
Amantadine—MAOB—endometrium—uterine cancer	0.000723	0.0292	CbGeAlD
Amantadine—MAOB—mammalian vulva—uterine cancer	0.000699	0.0282	CbGeAlD
Amantadine—SIGMAR1—uterus—uterine cancer	0.000696	0.0281	CbGeAlD
Amantadine—DDC—lymph node—uterine cancer	0.000681	0.0275	CbGeAlD
Amantadine—MAOB—uterus—uterine cancer	0.000666	0.0269	CbGeAlD
Amantadine—SLC22A1—vagina—uterine cancer	0.000612	0.0247	CbGeAlD
Amantadine—MAOB—female reproductive system—uterine cancer	0.000599	0.0242	CbGeAlD
Amantadine—Somnolence—Progesterone—uterine cancer	0.000579	0.0029	CcSEcCtD
Amantadine—Nervous system disorder—Medroxyprogesterone Acetate—uterine cancer	0.000579	0.0029	CcSEcCtD
Amantadine—Tachycardia—Medroxyprogesterone Acetate—uterine cancer	0.000576	0.00288	CcSEcCtD
Amantadine—Dyspepsia—Progesterone—uterine cancer	0.000574	0.00287	CcSEcCtD
Amantadine—Skin disorder—Medroxyprogesterone Acetate—uterine cancer	0.000573	0.00287	CcSEcCtD
Amantadine—Alopecia—Dactinomycin—uterine cancer	0.000573	0.00287	CcSEcCtD
Amantadine—Sweating increased—Etoposide—uterine cancer	0.000571	0.00286	CcSEcCtD
Amantadine—Hyperhidrosis—Medroxyprogesterone Acetate—uterine cancer	0.000571	0.00286	CcSEcCtD
Amantadine—SIGMAR1—female gonad—uterine cancer	0.000569	0.023	CbGeAlD
Amantadine—Decreased appetite—Progesterone—uterine cancer	0.000566	0.00284	CcSEcCtD
Amantadine—SIGMAR1—vagina—uterine cancer	0.000566	0.0229	CbGeAlD
Amantadine—Delirium—Doxorubicin—uterine cancer	0.000563	0.00282	CcSEcCtD
Amantadine—Anorexia—Medroxyprogesterone Acetate—uterine cancer	0.000563	0.00282	CcSEcCtD
Amantadine—Gastrointestinal disorder—Progesterone—uterine cancer	0.000562	0.00282	CcSEcCtD
Amantadine—Fatigue—Progesterone—uterine cancer	0.000562	0.00281	CcSEcCtD
Amantadine—Dyskinesia—Epirubicin—uterine cancer	0.000557	0.00279	CcSEcCtD
Amantadine—Constipation—Progesterone—uterine cancer	0.000557	0.00279	CcSEcCtD
Amantadine—Dysarthria—Epirubicin—uterine cancer	0.000554	0.00277	CcSEcCtD
Amantadine—Hypotension—Medroxyprogesterone Acetate—uterine cancer	0.000552	0.00276	CcSEcCtD
Amantadine—Neutropenia—Etoposide—uterine cancer	0.000548	0.00274	CcSEcCtD
Amantadine—MAOB—female gonad—uterine cancer	0.000545	0.022	CbGeAlD
Amantadine—MAOB—vagina—uterine cancer	0.000542	0.0219	CbGeAlD
Amantadine—Feeling abnormal—Progesterone—uterine cancer	0.000537	0.00269	CcSEcCtD
Amantadine—Gait disturbance—Epirubicin—uterine cancer	0.000537	0.00269	CcSEcCtD
Amantadine—Insomnia—Medroxyprogesterone Acetate—uterine cancer	0.000534	0.00267	CcSEcCtD
Amantadine—Paraesthesia—Medroxyprogesterone Acetate—uterine cancer	0.00053	0.00265	CcSEcCtD
Amantadine—Dyspnoea—Medroxyprogesterone Acetate—uterine cancer	0.000526	0.00263	CcSEcCtD
Amantadine—Somnolence—Medroxyprogesterone Acetate—uterine cancer	0.000525	0.00263	CcSEcCtD
Amantadine—Dyspepsia—Medroxyprogesterone Acetate—uterine cancer	0.00052	0.0026	CcSEcCtD
Amantadine—Dyskinesia—Doxorubicin—uterine cancer	0.000516	0.00258	CcSEcCtD
Amantadine—Body temperature increased—Progesterone—uterine cancer	0.000515	0.00258	CcSEcCtD
Amantadine—Decreased appetite—Medroxyprogesterone Acetate—uterine cancer	0.000513	0.00257	CcSEcCtD
Amantadine—Dysarthria—Doxorubicin—uterine cancer	0.000512	0.00256	CcSEcCtD
Amantadine—Gastrointestinal disorder—Medroxyprogesterone Acetate—uterine cancer	0.00051	0.00255	CcSEcCtD
Amantadine—Fatigue—Medroxyprogesterone Acetate—uterine cancer	0.000509	0.00255	CcSEcCtD
Amantadine—Leukopenia—Dactinomycin—uterine cancer	0.000505	0.00253	CcSEcCtD
Amantadine—Constipation—Medroxyprogesterone Acetate—uterine cancer	0.000505	0.00253	CcSEcCtD
Amantadine—Gait disturbance—Doxorubicin—uterine cancer	0.000496	0.00249	CcSEcCtD
Amantadine—Agranulocytosis—Etoposide—uterine cancer	0.000488	0.00244	CcSEcCtD
Amantadine—Feeling abnormal—Medroxyprogesterone Acetate—uterine cancer	0.000487	0.00244	CcSEcCtD
Amantadine—Hypersensitivity—Progesterone—uterine cancer	0.00048	0.0024	CcSEcCtD
Amantadine—Coma—Epirubicin—uterine cancer	0.000478	0.0024	CcSEcCtD
Amantadine—Asthenia—Progesterone—uterine cancer	0.000467	0.00234	CcSEcCtD
Amantadine—Body temperature increased—Medroxyprogesterone Acetate—uterine cancer	0.000467	0.00234	CcSEcCtD
Amantadine—Pulmonary oedema—Epirubicin—uterine cancer	0.000466	0.00233	CcSEcCtD
Amantadine—Urinary tract disorder—Etoposide—uterine cancer	0.000463	0.00232	CcSEcCtD
Amantadine—Pruritus—Progesterone—uterine cancer	0.000461	0.00231	CcSEcCtD
Amantadine—Oedema—Dactinomycin—uterine cancer	0.00046	0.00231	CcSEcCtD
Amantadine—Urethral disorder—Etoposide—uterine cancer	0.00046	0.0023	CcSEcCtD
Amantadine—Hypertonia—Epirubicin—uterine cancer	0.000459	0.0023	CcSEcCtD
Amantadine—Mental disability—Epirubicin—uterine cancer	0.000454	0.00227	CcSEcCtD
Amantadine—Diarrhoea—Progesterone—uterine cancer	0.000446	0.00223	CcSEcCtD
Amantadine—Coma—Doxorubicin—uterine cancer	0.000443	0.00222	CcSEcCtD
Amantadine—Anorexia—Dactinomycin—uterine cancer	0.000439	0.0022	CcSEcCtD
Amantadine—Eye disorder—Etoposide—uterine cancer	0.000438	0.00219	CcSEcCtD
Amantadine—Cardiac disorder—Etoposide—uterine cancer	0.000435	0.00218	CcSEcCtD
Amantadine—Hypersensitivity—Medroxyprogesterone Acetate—uterine cancer	0.000435	0.00218	CcSEcCtD
Amantadine—Photosensitivity—Epirubicin—uterine cancer	0.000433	0.00217	CcSEcCtD
Amantadine—Pulmonary oedema—Doxorubicin—uterine cancer	0.000431	0.00216	CcSEcCtD
Amantadine—Dizziness—Progesterone—uterine cancer	0.000431	0.00216	CcSEcCtD
Amantadine—Angiopathy—Etoposide—uterine cancer	0.000426	0.00213	CcSEcCtD
Amantadine—Hypertonia—Doxorubicin—uterine cancer	0.000425	0.00213	CcSEcCtD
Amantadine—Asthenia—Medroxyprogesterone Acetate—uterine cancer	0.000424	0.00212	CcSEcCtD
Amantadine—Eczema—Epirubicin—uterine cancer	0.000423	0.00212	CcSEcCtD
Amantadine—Mediastinal disorder—Etoposide—uterine cancer	0.000423	0.00212	CcSEcCtD
Amantadine—Mental disability—Doxorubicin—uterine cancer	0.00042	0.0021	CcSEcCtD
Amantadine—Cardiac failure congestive—Epirubicin—uterine cancer	0.000419	0.0021	CcSEcCtD
Amantadine—Pruritus—Medroxyprogesterone Acetate—uterine cancer	0.000418	0.00209	CcSEcCtD
Amantadine—Alopecia—Etoposide—uterine cancer	0.000415	0.00208	CcSEcCtD
Amantadine—Vomiting—Progesterone—uterine cancer	0.000414	0.00207	CcSEcCtD
Amantadine—Renal failure acute—Epirubicin—uterine cancer	0.000412	0.00206	CcSEcCtD
Amantadine—Rash—Progesterone—uterine cancer	0.000411	0.00206	CcSEcCtD
Amantadine—Dermatitis—Progesterone—uterine cancer	0.00041	0.00205	CcSEcCtD
Amantadine—Headache—Progesterone—uterine cancer	0.000408	0.00204	CcSEcCtD
Amantadine—Diarrhoea—Medroxyprogesterone Acetate—uterine cancer	0.000404	0.00202	CcSEcCtD
Amantadine—Photosensitivity—Doxorubicin—uterine cancer	0.000401	0.00201	CcSEcCtD
Amantadine—Decreased appetite—Dactinomycin—uterine cancer	0.0004	0.002	CcSEcCtD
Amantadine—Fatigue—Dactinomycin—uterine cancer	0.000397	0.00199	CcSEcCtD
Amantadine—Eczema—Doxorubicin—uterine cancer	0.000391	0.00196	CcSEcCtD
Amantadine—Dizziness—Medroxyprogesterone Acetate—uterine cancer	0.00039	0.00195	CcSEcCtD
Amantadine—Cardiac failure—Epirubicin—uterine cancer	0.000389	0.00195	CcSEcCtD
Amantadine—Lethargy—Epirubicin—uterine cancer	0.000388	0.00194	CcSEcCtD
Amantadine—Cardiac failure congestive—Doxorubicin—uterine cancer	0.000388	0.00194	CcSEcCtD
Amantadine—Nausea—Progesterone—uterine cancer	0.000387	0.00194	CcSEcCtD
Amantadine—Renal failure acute—Doxorubicin—uterine cancer	0.000381	0.00191	CcSEcCtD
Amantadine—Osteoarthritis—Epirubicin—uterine cancer	0.00038	0.0019	CcSEcCtD
Amantadine—Feeling abnormal—Dactinomycin—uterine cancer	0.000379	0.0019	CcSEcCtD
Amantadine—Vomiting—Medroxyprogesterone Acetate—uterine cancer	0.000375	0.00188	CcSEcCtD
Amantadine—ABCB1—myometrium—uterine cancer	0.000375	0.0151	CbGeAlD
Amantadine—Rash—Medroxyprogesterone Acetate—uterine cancer	0.000372	0.00186	CcSEcCtD
Amantadine—Dermatitis—Medroxyprogesterone Acetate—uterine cancer	0.000372	0.00186	CcSEcCtD
Amantadine—Headache—Medroxyprogesterone Acetate—uterine cancer	0.00037	0.00185	CcSEcCtD
Amantadine—SIGMAR1—lymph node—uterine cancer	0.000366	0.0148	CbGeAlD
Amantadine—Leukopenia—Etoposide—uterine cancer	0.000366	0.00183	CcSEcCtD
Amantadine—Body temperature increased—Dactinomycin—uterine cancer	0.000364	0.00182	CcSEcCtD
Amantadine—Cardiac arrest—Epirubicin—uterine cancer	0.000361	0.00181	CcSEcCtD
Amantadine—Cardiac failure—Doxorubicin—uterine cancer	0.00036	0.0018	CcSEcCtD
Amantadine—Lethargy—Doxorubicin—uterine cancer	0.000359	0.0018	CcSEcCtD
Amantadine—Ataxia—Epirubicin—uterine cancer	0.000357	0.00179	CcSEcCtD
Amantadine—Convulsion—Etoposide—uterine cancer	0.000354	0.00177	CcSEcCtD
Amantadine—Hypertension—Etoposide—uterine cancer	0.000353	0.00176	CcSEcCtD
Amantadine—Osteoarthritis—Doxorubicin—uterine cancer	0.000352	0.00176	CcSEcCtD
Amantadine—Liver function test abnormal—Epirubicin—uterine cancer	0.000351	0.00176	CcSEcCtD
Amantadine—Nausea—Medroxyprogesterone Acetate—uterine cancer	0.000351	0.00176	CcSEcCtD
Amantadine—MAOB—lymph node—uterine cancer	0.00035	0.0142	CbGeAlD
Amantadine—Orthostatic hypotension—Epirubicin—uterine cancer	0.000347	0.00174	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Etoposide—uterine cancer	0.000345	0.00173	CcSEcCtD
Amantadine—Hypersensitivity—Dactinomycin—uterine cancer	0.000339	0.0017	CcSEcCtD
Amantadine—Confusional state—Etoposide—uterine cancer	0.000336	0.00168	CcSEcCtD
Amantadine—Cardiac arrest—Doxorubicin—uterine cancer	0.000334	0.00167	CcSEcCtD
Amantadine—Anaphylactic shock—Etoposide—uterine cancer	0.000333	0.00167	CcSEcCtD
Amantadine—Ataxia—Doxorubicin—uterine cancer	0.000331	0.00166	CcSEcCtD
Amantadine—Asthenia—Dactinomycin—uterine cancer	0.00033	0.00165	CcSEcCtD
Amantadine—Dysphagia—Epirubicin—uterine cancer	0.000329	0.00164	CcSEcCtD
Amantadine—Tachycardia—Etoposide—uterine cancer	0.000325	0.00163	CcSEcCtD
Amantadine—Liver function test abnormal—Doxorubicin—uterine cancer	0.000325	0.00163	CcSEcCtD
Amantadine—Skin disorder—Etoposide—uterine cancer	0.000324	0.00162	CcSEcCtD
Amantadine—Hyperhidrosis—Etoposide—uterine cancer	0.000322	0.00161	CcSEcCtD
Amantadine—Orthostatic hypotension—Doxorubicin—uterine cancer	0.000321	0.00161	CcSEcCtD
Amantadine—Anorexia—Etoposide—uterine cancer	0.000318	0.00159	CcSEcCtD
Amantadine—Diarrhoea—Dactinomycin—uterine cancer	0.000315	0.00158	CcSEcCtD
Amantadine—Hypotension—Etoposide—uterine cancer	0.000311	0.00156	CcSEcCtD
Amantadine—Neutropenia—Epirubicin—uterine cancer	0.000307	0.00154	CcSEcCtD
Amantadine—Dysphagia—Doxorubicin—uterine cancer	0.000304	0.00152	CcSEcCtD
Amantadine—Photosensitivity reaction—Epirubicin—uterine cancer	0.0003	0.0015	CcSEcCtD
Amantadine—Paraesthesia—Etoposide—uterine cancer	0.000299	0.0015	CcSEcCtD
Amantadine—Dyspnoea—Etoposide—uterine cancer	0.000297	0.00149	CcSEcCtD
Amantadine—Somnolence—Etoposide—uterine cancer	0.000296	0.00148	CcSEcCtD
Amantadine—ABCB1—epithelium—uterine cancer	0.000294	0.0119	CbGeAlD
Amantadine—Vomiting—Dactinomycin—uterine cancer	0.000293	0.00147	CcSEcCtD
Amantadine—ABCB1—uterine cervix—uterine cancer	0.000291	0.0118	CbGeAlD
Amantadine—Rash—Dactinomycin—uterine cancer	0.00029	0.00145	CcSEcCtD
Amantadine—Decreased appetite—Etoposide—uterine cancer	0.00029	0.00145	CcSEcCtD
Amantadine—Gastrointestinal disorder—Etoposide—uterine cancer	0.000288	0.00144	CcSEcCtD
Amantadine—Fatigue—Etoposide—uterine cancer	0.000287	0.00144	CcSEcCtD
Amantadine—Constipation—Etoposide—uterine cancer	0.000285	0.00143	CcSEcCtD
Amantadine—Neutropenia—Doxorubicin—uterine cancer	0.000284	0.00142	CcSEcCtD
Amantadine—ABCB1—decidua—uterine cancer	0.000278	0.0112	CbGeAlD
Amantadine—Photosensitivity reaction—Doxorubicin—uterine cancer	0.000277	0.00139	CcSEcCtD
Amantadine—Feeling abnormal—Etoposide—uterine cancer	0.000275	0.00137	CcSEcCtD
Amantadine—Nausea—Dactinomycin—uterine cancer	0.000274	0.00137	CcSEcCtD
Amantadine—Agranulocytosis—Epirubicin—uterine cancer	0.000273	0.00137	CcSEcCtD
Amantadine—ABCB1—renal system—uterine cancer	0.000273	0.011	CbGeAlD
Amantadine—ABCB1—endometrium—uterine cancer	0.000264	0.0107	CbGeAlD
Amantadine—Body temperature increased—Etoposide—uterine cancer	0.000263	0.00132	CcSEcCtD
Amantadine—Urinary tract disorder—Epirubicin—uterine cancer	0.00026	0.0013	CcSEcCtD
Amantadine—Oedema peripheral—Epirubicin—uterine cancer	0.000259	0.0013	CcSEcCtD
Amantadine—Urethral disorder—Epirubicin—uterine cancer	0.000258	0.00129	CcSEcCtD
Amantadine—ABCB1—mammalian vulva—uterine cancer	0.000255	0.0103	CbGeAlD
Amantadine—Visual impairment—Epirubicin—uterine cancer	0.000253	0.00127	CcSEcCtD
Amantadine—Agranulocytosis—Doxorubicin—uterine cancer	0.000253	0.00127	CcSEcCtD
Amantadine—Eye disorder—Epirubicin—uterine cancer	0.000246	0.00123	CcSEcCtD
Amantadine—Hypersensitivity—Etoposide—uterine cancer	0.000246	0.00123	CcSEcCtD
Amantadine—Cardiac disorder—Epirubicin—uterine cancer	0.000244	0.00122	CcSEcCtD
Amantadine—ABCB1—uterus—uterine cancer	0.000243	0.00982	CbGeAlD
Amantadine—Urinary tract disorder—Doxorubicin—uterine cancer	0.00024	0.0012	CcSEcCtD
Amantadine—Oedema peripheral—Doxorubicin—uterine cancer	0.00024	0.0012	CcSEcCtD
Amantadine—Asthenia—Etoposide—uterine cancer	0.000239	0.0012	CcSEcCtD
Amantadine—Angiopathy—Epirubicin—uterine cancer	0.000239	0.00119	CcSEcCtD
Amantadine—Urethral disorder—Doxorubicin—uterine cancer	0.000239	0.00119	CcSEcCtD
Amantadine—Mediastinal disorder—Epirubicin—uterine cancer	0.000237	0.00119	CcSEcCtD
Amantadine—Pruritus—Etoposide—uterine cancer	0.000236	0.00118	CcSEcCtD
Amantadine—Arrhythmia—Epirubicin—uterine cancer	0.000235	0.00118	CcSEcCtD
Amantadine—Visual impairment—Doxorubicin—uterine cancer	0.000234	0.00117	CcSEcCtD
Amantadine—Alopecia—Epirubicin—uterine cancer	0.000232	0.00116	CcSEcCtD
Amantadine—Mental disorder—Epirubicin—uterine cancer	0.00023	0.00115	CcSEcCtD
Amantadine—Malnutrition—Epirubicin—uterine cancer	0.000229	0.00115	CcSEcCtD
Amantadine—Diarrhoea—Etoposide—uterine cancer	0.000228	0.00114	CcSEcCtD
Amantadine—Eye disorder—Doxorubicin—uterine cancer	0.000227	0.00114	CcSEcCtD
Amantadine—Cardiac disorder—Doxorubicin—uterine cancer	0.000226	0.00113	CcSEcCtD
Amantadine—Tension—Epirubicin—uterine cancer	0.000225	0.00112	CcSEcCtD
Amantadine—Nervousness—Epirubicin—uterine cancer	0.000222	0.00111	CcSEcCtD
Amantadine—Angiopathy—Doxorubicin—uterine cancer	0.000221	0.00111	CcSEcCtD
Amantadine—Dizziness—Etoposide—uterine cancer	0.00022	0.0011	CcSEcCtD
Amantadine—Mediastinal disorder—Doxorubicin—uterine cancer	0.000219	0.0011	CcSEcCtD
Amantadine—ABCB1—female reproductive system—uterine cancer	0.000218	0.00882	CbGeAlD
Amantadine—Arrhythmia—Doxorubicin—uterine cancer	0.000217	0.00109	CcSEcCtD
Amantadine—Vision blurred—Epirubicin—uterine cancer	0.000216	0.00108	CcSEcCtD
Amantadine—Alopecia—Doxorubicin—uterine cancer	0.000215	0.00108	CcSEcCtD
Amantadine—Mental disorder—Doxorubicin—uterine cancer	0.000213	0.00107	CcSEcCtD
Amantadine—Vomiting—Etoposide—uterine cancer	0.000212	0.00106	CcSEcCtD
Amantadine—Malnutrition—Doxorubicin—uterine cancer	0.000212	0.00106	CcSEcCtD
Amantadine—Agitation—Epirubicin—uterine cancer	0.00021	0.00105	CcSEcCtD
Amantadine—Rash—Etoposide—uterine cancer	0.00021	0.00105	CcSEcCtD
Amantadine—Dermatitis—Etoposide—uterine cancer	0.00021	0.00105	CcSEcCtD
Amantadine—Headache—Etoposide—uterine cancer	0.000209	0.00105	CcSEcCtD
Amantadine—Tension—Doxorubicin—uterine cancer	0.000208	0.00104	CcSEcCtD
Amantadine—Nervousness—Doxorubicin—uterine cancer	0.000206	0.00103	CcSEcCtD
Amantadine—Leukopenia—Epirubicin—uterine cancer	0.000205	0.00103	CcSEcCtD
Amantadine—Palpitations—Epirubicin—uterine cancer	0.000202	0.00101	CcSEcCtD
Amantadine—Vision blurred—Doxorubicin—uterine cancer	0.0002	0.000999	CcSEcCtD
Amantadine—ABCB1—female gonad—uterine cancer	0.000199	0.00803	CbGeAlD
Amantadine—Convulsion—Epirubicin—uterine cancer	0.000198	0.000993	CcSEcCtD
Amantadine—Nausea—Etoposide—uterine cancer	0.000198	0.000991	CcSEcCtD
Amantadine—Hypertension—Epirubicin—uterine cancer	0.000198	0.000989	CcSEcCtD
Amantadine—ABCB1—vagina—uterine cancer	0.000198	0.00798	CbGeAlD
Amantadine—Agitation—Doxorubicin—uterine cancer	0.000195	0.000974	CcSEcCtD
Amantadine—Anxiety—Epirubicin—uterine cancer	0.000194	0.000972	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—uterine cancer	0.000194	0.000969	CcSEcCtD
Amantadine—Dry mouth—Epirubicin—uterine cancer	0.000191	0.000954	CcSEcCtD
Amantadine—Leukopenia—Doxorubicin—uterine cancer	0.00019	0.000949	CcSEcCtD
Amantadine—Confusional state—Epirubicin—uterine cancer	0.000188	0.000943	CcSEcCtD
Amantadine—Palpitations—Doxorubicin—uterine cancer	0.000187	0.000937	CcSEcCtD
Amantadine—Anaphylactic shock—Epirubicin—uterine cancer	0.000187	0.000935	CcSEcCtD
Amantadine—Oedema—Epirubicin—uterine cancer	0.000187	0.000935	CcSEcCtD
Amantadine—Convulsion—Doxorubicin—uterine cancer	0.000184	0.000919	CcSEcCtD
Amantadine—Nervous system disorder—Epirubicin—uterine cancer	0.000183	0.000917	CcSEcCtD
Amantadine—Hypertension—Doxorubicin—uterine cancer	0.000183	0.000915	CcSEcCtD
Amantadine—Tachycardia—Epirubicin—uterine cancer	0.000182	0.000913	CcSEcCtD
Amantadine—Skin disorder—Epirubicin—uterine cancer	0.000181	0.000908	CcSEcCtD
Amantadine—Hyperhidrosis—Epirubicin—uterine cancer	0.000181	0.000904	CcSEcCtD
Amantadine—Anxiety—Doxorubicin—uterine cancer	0.00018	0.0009	CcSEcCtD
Amantadine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—uterine cancer	0.000179	0.000896	CcSEcCtD
Amantadine—Anorexia—Epirubicin—uterine cancer	0.000178	0.000891	CcSEcCtD
Amantadine—Dry mouth—Doxorubicin—uterine cancer	0.000176	0.000883	CcSEcCtD
Amantadine—Hypotension—Epirubicin—uterine cancer	0.000175	0.000874	CcSEcCtD
Amantadine—Confusional state—Doxorubicin—uterine cancer	0.000174	0.000873	CcSEcCtD
Amantadine—Anaphylactic shock—Doxorubicin—uterine cancer	0.000173	0.000865	CcSEcCtD
Amantadine—Oedema—Doxorubicin—uterine cancer	0.000173	0.000865	CcSEcCtD
Amantadine—Nervous system disorder—Doxorubicin—uterine cancer	0.00017	0.000849	CcSEcCtD
Amantadine—Insomnia—Epirubicin—uterine cancer	0.000169	0.000846	CcSEcCtD
Amantadine—Tachycardia—Doxorubicin—uterine cancer	0.000169	0.000845	CcSEcCtD
Amantadine—Skin disorder—Doxorubicin—uterine cancer	0.000168	0.000841	CcSEcCtD
Amantadine—Paraesthesia—Epirubicin—uterine cancer	0.000168	0.00084	CcSEcCtD
Amantadine—Hyperhidrosis—Doxorubicin—uterine cancer	0.000167	0.000837	CcSEcCtD
Amantadine—Dyspnoea—Epirubicin—uterine cancer	0.000167	0.000834	CcSEcCtD
Amantadine—Somnolence—Epirubicin—uterine cancer	0.000166	0.000831	CcSEcCtD
Amantadine—Anorexia—Doxorubicin—uterine cancer	0.000165	0.000825	CcSEcCtD
Amantadine—Dyspepsia—Epirubicin—uterine cancer	0.000164	0.000823	CcSEcCtD
Amantadine—Decreased appetite—Epirubicin—uterine cancer	0.000162	0.000813	CcSEcCtD
Amantadine—Hypotension—Doxorubicin—uterine cancer	0.000162	0.000809	CcSEcCtD
Amantadine—Gastrointestinal disorder—Epirubicin—uterine cancer	0.000161	0.000807	CcSEcCtD
Amantadine—Fatigue—Epirubicin—uterine cancer	0.000161	0.000806	CcSEcCtD
Amantadine—Constipation—Epirubicin—uterine cancer	0.00016	0.0008	CcSEcCtD
Amantadine—Insomnia—Doxorubicin—uterine cancer	0.000156	0.000783	CcSEcCtD
Amantadine—Paraesthesia—Doxorubicin—uterine cancer	0.000155	0.000777	CcSEcCtD
Amantadine—Dyspnoea—Doxorubicin—uterine cancer	0.000154	0.000772	CcSEcCtD
Amantadine—Feeling abnormal—Epirubicin—uterine cancer	0.000154	0.000771	CcSEcCtD
Amantadine—Somnolence—Doxorubicin—uterine cancer	0.000154	0.000769	CcSEcCtD
Amantadine—Dyspepsia—Doxorubicin—uterine cancer	0.000152	0.000762	CcSEcCtD
Amantadine—Decreased appetite—Doxorubicin—uterine cancer	0.00015	0.000752	CcSEcCtD
Amantadine—Gastrointestinal disorder—Doxorubicin—uterine cancer	0.000149	0.000747	CcSEcCtD
Amantadine—Fatigue—Doxorubicin—uterine cancer	0.000149	0.000746	CcSEcCtD
Amantadine—Constipation—Doxorubicin—uterine cancer	0.000148	0.00074	CcSEcCtD
Amantadine—Body temperature increased—Epirubicin—uterine cancer	0.000148	0.000739	CcSEcCtD
Amantadine—Feeling abnormal—Doxorubicin—uterine cancer	0.000142	0.000713	CcSEcCtD
Amantadine—Hypersensitivity—Epirubicin—uterine cancer	0.000138	0.000689	CcSEcCtD
Amantadine—Body temperature increased—Doxorubicin—uterine cancer	0.000137	0.000684	CcSEcCtD
Amantadine—Asthenia—Epirubicin—uterine cancer	0.000134	0.000671	CcSEcCtD
Amantadine—Pruritus—Epirubicin—uterine cancer	0.000132	0.000662	CcSEcCtD
Amantadine—Diarrhoea—Epirubicin—uterine cancer	0.000128	0.00064	CcSEcCtD
Amantadine—ABCB1—lymph node—uterine cancer	0.000128	0.00516	CbGeAlD
Amantadine—Hypersensitivity—Doxorubicin—uterine cancer	0.000127	0.000638	CcSEcCtD
Amantadine—Asthenia—Doxorubicin—uterine cancer	0.000124	0.000621	CcSEcCtD
Amantadine—Dizziness—Epirubicin—uterine cancer	0.000124	0.000618	CcSEcCtD
Amantadine—Pruritus—Doxorubicin—uterine cancer	0.000122	0.000612	CcSEcCtD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—MAP3K4—uterine cancer	0.000121	0.00503	CbGpPWpGaD
Amantadine—GRIN1—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	0.00012	0.00499	CbGpPWpGaD
Amantadine—GRIN1—EPHB-mediated forward signaling—HRAS—uterine cancer	0.00012	0.00499	CbGpPWpGaD
Amantadine—Vomiting—Epirubicin—uterine cancer	0.000119	0.000595	CcSEcCtD
Amantadine—Diarrhoea—Doxorubicin—uterine cancer	0.000118	0.000592	CcSEcCtD
Amantadine—Rash—Epirubicin—uterine cancer	0.000118	0.00059	CcSEcCtD
Amantadine—Dermatitis—Epirubicin—uterine cancer	0.000118	0.000589	CcSEcCtD
Amantadine—GRIN2B—Activation of NMDA receptor upon glutamate binding and postsynaptic events—HRAS—uterine cancer	0.000117	0.00487	CbGpPWpGaD
Amantadine—GRIN2B—EPHB-mediated forward signaling—HRAS—uterine cancer	0.000117	0.00487	CbGpPWpGaD
Amantadine—Headache—Epirubicin—uterine cancer	0.000117	0.000586	CcSEcCtD
Amantadine—Dizziness—Doxorubicin—uterine cancer	0.000114	0.000572	CcSEcCtD
Amantadine—SLC22A2—Neuronal System—ABCC9—uterine cancer	0.000112	0.00466	CbGpPWpGaD
Amantadine—GRIN2C—Alzheimers Disease—TP53—uterine cancer	0.000112	0.00464	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HNF1B—uterine cancer	0.000111	0.00463	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CCL2—uterine cancer	0.000111	0.00462	CbGpPWpGaD
Amantadine—Nausea—Epirubicin—uterine cancer	0.000111	0.000556	CcSEcCtD
Amantadine—Vomiting—Doxorubicin—uterine cancer	0.00011	0.00055	CcSEcCtD
Amantadine—Rash—Doxorubicin—uterine cancer	0.000109	0.000546	CcSEcCtD
Amantadine—Dermatitis—Doxorubicin—uterine cancer	0.000109	0.000545	CcSEcCtD
Amantadine—GRIN2B—Developmental Biology—HNF1B—uterine cancer	0.000109	0.00451	CbGpPWpGaD
Amantadine—Headache—Doxorubicin—uterine cancer	0.000108	0.000542	CcSEcCtD
Amantadine—DRD2—Circadian rythm related genes—HNF1B—uterine cancer	0.000105	0.00436	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—ABCC9—uterine cancer	0.000105	0.00434	CbGpPWpGaD
Amantadine—GRIN2D—Alzheimers Disease—TP53—uterine cancer	0.000104	0.00431	CbGpPWpGaD
Amantadine—Nausea—Doxorubicin—uterine cancer	0.000103	0.000514	CcSEcCtD
Amantadine—GRIN1—Spinal Cord Injury—CXCL8—uterine cancer	8.8e-05	0.00365	CbGpPWpGaD
Amantadine—DDC—Metabolism—NDUFB11—uterine cancer	8.75e-05	0.00364	CbGpPWpGaD
Amantadine—DDC—Metabolism—SRD5A2—uterine cancer	8.75e-05	0.00364	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—CDKN1B—uterine cancer	8.59e-05	0.00357	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—VEGFA—uterine cancer	8.57e-05	0.00356	CbGpPWpGaD
Amantadine—GRIN2A—Alzheimers Disease—TP53—uterine cancer	8.53e-05	0.00354	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—VEGFA—uterine cancer	8.35e-05	0.00347	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—CXCL8—uterine cancer	8.19e-05	0.0034	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	7.56e-05	0.00314	CbGpPWpGaD
Amantadine—GRIN1—Alzheimers Disease—TP53—uterine cancer	7.44e-05	0.00309	CbGpPWpGaD
Amantadine—MAOB—Metabolism—SRD5A2—uterine cancer	7.37e-05	0.00306	CbGpPWpGaD
Amantadine—MAOB—Metabolism—NDUFB11—uterine cancer	7.37e-05	0.00306	CbGpPWpGaD
Amantadine—GRIN2B—Alzheimers Disease—TP53—uterine cancer	7.25e-05	0.00301	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CXCL8—uterine cancer	7.04e-05	0.00292	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—EP300—uterine cancer	7.02e-05	0.00292	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—SMAD3—uterine cancer	7e-05	0.00291	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—CTNNB1—uterine cancer	6.92e-05	0.00287	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—INHBA—uterine cancer	6.77e-05	0.00281	CbGpPWpGaD
Amantadine—GRIN2C—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	6.76e-05	0.00281	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—CTNNB1—uterine cancer	6.75e-05	0.0028	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EZH2—uterine cancer	6.74e-05	0.0028	CbGpPWpGaD
Amantadine—DDC—SIDS Susceptibility Pathways—VEGFA—uterine cancer	6.65e-05	0.00276	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—CTNNB1—uterine cancer	6.49e-05	0.0027	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKR1B1—uterine cancer	6.33e-05	0.00263	CbGpPWpGaD
Amantadine—DDC—Metabolism—STAR—uterine cancer	6.33e-05	0.00263	CbGpPWpGaD
Amantadine—GRIN2D—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	6.29e-05	0.00261	CbGpPWpGaD
Amantadine—GRIN1—EPH-Ephrin signaling—HRAS—uterine cancer	6.19e-05	0.00257	CbGpPWpGaD
Amantadine—GRIN2B—EPH-Ephrin signaling—HRAS—uterine cancer	6.04e-05	0.00251	CbGpPWpGaD
Amantadine—SLC22A2—Transmembrane transport of small molecules—ABCC9—uterine cancer	6.04e-05	0.00251	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—EP300—uterine cancer	6.03e-05	0.00251	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—PTEN—uterine cancer	6.01e-05	0.0025	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—EP300—uterine cancer	5.73e-05	0.00238	CbGpPWpGaD
Amantadine—GRIN1—SIDS Susceptibility Pathways—VEGFA—uterine cancer	5.71e-05	0.00237	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—MET—uterine cancer	5.66e-05	0.00235	CbGpPWpGaD
Amantadine—SLC22A1—Transmembrane transport of small molecules—ABCC9—uterine cancer	5.63e-05	0.00234	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—MET—uterine cancer	5.51e-05	0.00229	CbGpPWpGaD
Amantadine—GRIN1—Spinal Cord Injury—TP53—uterine cancer	5.4e-05	0.00224	CbGpPWpGaD
Amantadine—MAOB—Metabolism—STAR—uterine cancer	5.33e-05	0.00221	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKR1B1—uterine cancer	5.33e-05	0.00221	CbGpPWpGaD
Amantadine—GRIN2A—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	5.16e-05	0.00214	CbGpPWpGaD
Amantadine—GRIN2C—Transmission across Chemical Synapses—HRAS—uterine cancer	5.08e-05	0.00211	CbGpPWpGaD
Amantadine—DDC—Metabolism—POLD1—uterine cancer	4.97e-05	0.00206	CbGpPWpGaD
Amantadine—ABCB1—Imatinib Resistance in Chronic Myeloid Leukemia—CDKN1B—uterine cancer	4.93e-05	0.00205	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—SMAD3—uterine cancer	4.93e-05	0.00205	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—SMAD3—uterine cancer	4.8e-05	0.00199	CbGpPWpGaD
Amantadine—GRIN2D—Transmission across Chemical Synapses—HRAS—uterine cancer	4.73e-05	0.00196	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKR1C1—uterine cancer	4.65e-05	0.00193	CbGpPWpGaD
Amantadine—GRIN1—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.5e-05	0.00187	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—HRAS—uterine cancer	4.4e-05	0.00183	CbGpPWpGaD
Amantadine—GRIN2B—Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell—HRAS—uterine cancer	4.39e-05	0.00182	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EZH2—uterine cancer	4.34e-05	0.0018	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—HRAS—uterine cancer	4.29e-05	0.00178	CbGpPWpGaD
Amantadine—MAOB—Metabolism—POLD1—uterine cancer	4.18e-05	0.00174	CbGpPWpGaD
Amantadine—DDC—Metabolism—RRM2—uterine cancer	4.14e-05	0.00172	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—ERBB2—uterine cancer	4.13e-05	0.00172	CbGpPWpGaD
Amantadine—DDC—Circadian rythm related genes—TP53—uterine cancer	4.1e-05	0.0017	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—MET—uterine cancer	4.04e-05	0.00168	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—ERBB2—uterine cancer	4.03e-05	0.00167	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR2—uterine cancer	4.03e-05	0.00167	CbGpPWpGaD
Amantadine—DDC—Metabolism—DCN—uterine cancer	4.02e-05	0.00167	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—MET—uterine cancer	3.94e-05	0.00163	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—SRD5A2—uterine cancer	3.91e-05	0.00162	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—NDUFB11—uterine cancer	3.91e-05	0.00162	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKR1C1—uterine cancer	3.91e-05	0.00162	CbGpPWpGaD
Amantadine—GRIN2C—Neuronal System—HRAS—uterine cancer	3.89e-05	0.00162	CbGpPWpGaD
Amantadine—GRIN1—BDNF signaling pathway—AKT1—uterine cancer	3.89e-05	0.00161	CbGpPWpGaD
Amantadine—GRIN2A—Transmission across Chemical Synapses—HRAS—uterine cancer	3.88e-05	0.00161	CbGpPWpGaD
Amantadine—GRIN2B—BDNF signaling pathway—AKT1—uterine cancer	3.79e-05	0.00157	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP11A1—uterine cancer	3.79e-05	0.00157	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—STK11—uterine cancer	3.66e-05	0.00152	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—SRD5A2—uterine cancer	3.64e-05	0.00151	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—NDUFB11—uterine cancer	3.64e-05	0.00151	CbGpPWpGaD
Amantadine—GRIN2D—Neuronal System—HRAS—uterine cancer	3.62e-05	0.0015	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKR1C3—uterine cancer	3.58e-05	0.00148	CbGpPWpGaD
Amantadine—MAOB—Metabolism—RRM2—uterine cancer	3.49e-05	0.00145	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—CXCL8—uterine cancer	3.44e-05	0.00143	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—EP300—uterine cancer	3.41e-05	0.00142	CbGpPWpGaD
Amantadine—GRIN1—Transmission across Chemical Synapses—HRAS—uterine cancer	3.39e-05	0.00141	CbGpPWpGaD
Amantadine—MAOB—Metabolism—DCN—uterine cancer	3.38e-05	0.0014	CbGpPWpGaD
Amantadine—GRIN2B—Transmission across Chemical Synapses—HRAS—uterine cancer	3.3e-05	0.00137	CbGpPWpGaD
Amantadine—ABCB1—Transmembrane transport of small molecules—ABCC9—uterine cancer	3.3e-05	0.00137	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN2B—uterine cancer	3.28e-05	0.00136	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—VEGFA—uterine cancer	3.23e-05	0.00134	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP11A1—uterine cancer	3.19e-05	0.00132	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—VEGFA—uterine cancer	3.18e-05	0.00132	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—NRAS—uterine cancer	3.15e-05	0.00131	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—VEGFA—uterine cancer	3.1e-05	0.00129	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—NRAS—uterine cancer	3.07e-05	0.00127	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKR1C3—uterine cancer	3.01e-05	0.00125	CbGpPWpGaD
Amantadine—GRIN2A—Neuronal System—HRAS—uterine cancer	2.97e-05	0.00123	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—ERBB2—uterine cancer	2.95e-05	0.00123	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—ERBB2—uterine cancer	2.88e-05	0.00119	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—STAR—uterine cancer	2.83e-05	0.00117	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKR1B1—uterine cancer	2.83e-05	0.00117	CbGpPWpGaD
Amantadine—ABCB1—Allograft Rejection—VEGFA—uterine cancer	2.8e-05	0.00116	CbGpPWpGaD
Amantadine—DDC—Metabolism—STK11—uterine cancer	2.79e-05	0.00116	CbGpPWpGaD
Amantadine—DDC—Metabolism—CYP19A1—uterine cancer	2.79e-05	0.00116	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—KRAS—uterine cancer	2.71e-05	0.00112	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—KRAS—uterine cancer	2.64e-05	0.0011	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKR1B1—uterine cancer	2.63e-05	0.00109	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—STAR—uterine cancer	2.63e-05	0.00109	CbGpPWpGaD
Amantadine—GRIN1—Neuronal System—HRAS—uterine cancer	2.59e-05	0.00108	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—CTNNB1—uterine cancer	2.58e-05	0.00107	CbGpPWpGaD
Amantadine—GRIN2B—Neuronal System—HRAS—uterine cancer	2.53e-05	0.00105	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—CTNNB1—uterine cancer	2.52e-05	0.00104	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ESR1—uterine cancer	2.44e-05	0.00101	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—EP300—uterine cancer	2.4e-05	0.000996	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—PTEN—uterine cancer	2.37e-05	0.000984	CbGpPWpGaD
Amantadine—MAOB—Metabolism—CYP19A1—uterine cancer	2.35e-05	0.000974	CbGpPWpGaD
Amantadine—MAOB—Metabolism—STK11—uterine cancer	2.35e-05	0.000974	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CCL2—uterine cancer	2.34e-05	0.000971	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—EP300—uterine cancer	2.34e-05	0.000971	CbGpPWpGaD
Amantadine—DRD2—G alpha (i) signalling events—CXCL8—uterine cancer	2.33e-05	0.000966	CbGpPWpGaD
Amantadine—GRIN1—Axon guidance—HRAS—uterine cancer	2.3e-05	0.000956	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—VEGFA—uterine cancer	2.27e-05	0.000944	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—EP300—uterine cancer	2.26e-05	0.000939	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—NRAS—uterine cancer	2.24e-05	0.000932	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKR1B10—uterine cancer	2.24e-05	0.000932	CbGpPWpGaD
Amantadine—GRIN2B—Axon guidance—HRAS—uterine cancer	2.24e-05	0.000932	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—POLD1—uterine cancer	2.22e-05	0.000921	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—VEGFA—uterine cancer	2.22e-05	0.00092	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—NRAS—uterine cancer	2.19e-05	0.000909	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—SRD5A2—uterine cancer	2.14e-05	0.000887	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—NDUFB11—uterine cancer	2.14e-05	0.000887	CbGpPWpGaD
Amantadine—DDC—Metabolism—MTHFR—uterine cancer	2.09e-05	0.000869	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKR1C1—uterine cancer	2.07e-05	0.000862	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—POLD1—uterine cancer	2.07e-05	0.000859	CbGpPWpGaD
Amantadine—ABCB1—HIF-1-alpha transcription factor network—AKT1—uterine cancer	2.06e-05	0.000856	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKR1C1—uterine cancer	1.93e-05	0.000803	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—KRAS—uterine cancer	1.93e-05	0.000802	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—KRAS—uterine cancer	1.88e-05	0.000782	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—RNF43—uterine cancer	1.86e-05	0.000772	CbGpPWpGaD
Amantadine—DRD2—Class A/1 (Rhodopsin-like receptors)—CXCL8—uterine cancer	1.85e-05	0.000768	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—RRM2—uterine cancer	1.85e-05	0.000768	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—DCN—uterine cancer	1.8e-05	0.000745	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—ERBB2—uterine cancer	1.79e-05	0.000744	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CCL2—uterine cancer	1.78e-05	0.00074	CbGpPWpGaD
Amantadine—MAOB—Metabolism—MTHFR—uterine cancer	1.76e-05	0.000732	CbGpPWpGaD
Amantadine—SLC22A2—Transmission across Chemical Synapses—HRAS—uterine cancer	1.76e-05	0.000731	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—RRM2—uterine cancer	1.72e-05	0.000716	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—INHBA—uterine cancer	1.7e-05	0.000706	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP11A1—uterine cancer	1.69e-05	0.000702	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—DCN—uterine cancer	1.67e-05	0.000695	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CDKN1B—uterine cancer	1.66e-05	0.000689	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—HRAS—uterine cancer	1.64e-05	0.000682	CbGpPWpGaD
Amantadine—SLC22A1—Transmission across Chemical Synapses—HRAS—uterine cancer	1.64e-05	0.000681	CbGpPWpGaD
Amantadine—DRD2—Circadian rythm related genes—TP53—uterine cancer	1.62e-05	0.000672	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—HRAS—uterine cancer	1.6e-05	0.000665	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKR1C3—uterine cancer	1.6e-05	0.000663	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP11A1—uterine cancer	1.58e-05	0.000655	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—CTNNB1—uterine cancer	1.57e-05	0.000651	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKR1B1—uterine cancer	1.54e-05	0.000641	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—STAR—uterine cancer	1.54e-05	0.000641	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKR1C1—uterine cancer	1.53e-05	0.000636	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PTEN—uterine cancer	1.53e-05	0.000635	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKR1C3—uterine cancer	1.49e-05	0.000618	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—EP300—uterine cancer	1.46e-05	0.000605	CbGpPWpGaD
Amantadine—GRIN1—Developmental Biology—AKT1—uterine cancer	1.45e-05	0.000602	CbGpPWpGaD
Amantadine—GRIN2B—Developmental Biology—AKT1—uterine cancer	1.41e-05	0.000587	CbGpPWpGaD
Amantadine—DRD2—GPCR ligand binding—CXCL8—uterine cancer	1.41e-05	0.000585	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—VEGFA—uterine cancer	1.38e-05	0.000573	CbGpPWpGaD
Amantadine—SLC22A2—Neuronal System—HRAS—uterine cancer	1.35e-05	0.00056	CbGpPWpGaD
Amantadine—SLC22A1—Neuronal System—HRAS—uterine cancer	1.26e-05	0.000522	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—CYP19A1—uterine cancer	1.24e-05	0.000517	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—STK11—uterine cancer	1.24e-05	0.000517	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—POLD1—uterine cancer	1.21e-05	0.000503	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKR1C3—uterine cancer	1.18e-05	0.000489	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—KRAS—uterine cancer	1.17e-05	0.000487	CbGpPWpGaD
Amantadine—DDC—Metabolism—PTEN—uterine cancer	1.16e-05	0.000484	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—STK11—uterine cancer	1.16e-05	0.000482	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—CYP19A1—uterine cancer	1.16e-05	0.000482	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PGR—uterine cancer	1.15e-05	0.000477	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKR1C1—uterine cancer	1.13e-05	0.000471	CbGpPWpGaD
Amantadine—DDC—Metabolism—EP300—uterine cancer	1.11e-05	0.000461	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—YWHAE—uterine cancer	1.1e-05	0.000455	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—PIK3CA—uterine cancer	1.08e-05	0.000448	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FBXW7—uterine cancer	1.05e-05	0.000436	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—TP53—uterine cancer	1.04e-05	0.000433	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—RRM2—uterine cancer	1.01e-05	0.00042	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—DCN—uterine cancer	9.81e-06	0.000407	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PTEN—uterine cancer	9.8e-06	0.000407	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—MTHFR—uterine cancer	9.35e-06	0.000388	CbGpPWpGaD
Amantadine—MAOB—Metabolism—EP300—uterine cancer	9.35e-06	0.000388	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP11A1—uterine cancer	9.24e-06	0.000384	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—STK11—uterine cancer	9.18e-06	0.000381	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CCL2—uterine cancer	9.14e-06	0.00038	CbGpPWpGaD
Amantadine—ABCB1—Integrated Pancreatic Cancer Pathway—AKT1—uterine cancer	8.81e-06	0.000366	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKR1C3—uterine cancer	8.73e-06	0.000362	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—MTHFR—uterine cancer	8.72e-06	0.000362	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SOCS3—uterine cancer	8.6e-06	0.000357	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN2B—uterine cancer	8.23e-06	0.000342	CbGpPWpGaD
Amantadine—DDC—Metabolism—PIK3CA—uterine cancer	8.22e-06	0.000341	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—IGF1R—uterine cancer	7.99e-06	0.000332	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—CXCL8—uterine cancer	7.96e-06	0.00033	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—SMAD3—uterine cancer	7.52e-06	0.000312	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—CXCL8—uterine cancer	7.23e-06	0.0003	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—FGFR2—uterine cancer	7.17e-06	0.000298	CbGpPWpGaD
Amantadine—MAOB—Metabolism—PIK3CA—uterine cancer	6.92e-06	0.000287	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—STK11—uterine cancer	6.8e-06	0.000282	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—CYP19A1—uterine cancer	6.8e-06	0.000282	CbGpPWpGaD
Amantadine—DDC—Metabolism—AKT1—uterine cancer	6.71e-06	0.000279	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ESR1—uterine cancer	6.13e-06	0.000255	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—NRAS—uterine cancer	5.8e-06	0.000241	CbGpPWpGaD
Amantadine—MAOB—Metabolism—AKT1—uterine cancer	5.65e-06	0.000235	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CCL2—uterine cancer	5.4e-06	0.000224	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PTEN—uterine cancer	5.2e-06	0.000216	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—MTHFR—uterine cancer	5.11e-06	0.000212	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—PIK3CA—uterine cancer	5.05e-06	0.00021	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—KRAS—uterine cancer	4.99e-06	0.000207	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—EP300—uterine cancer	4.96e-06	0.000206	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PTEN—uterine cancer	4.85e-06	0.000201	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—EP300—uterine cancer	4.62e-06	0.000192	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—PIK3CA—uterine cancer	4.58e-06	0.00019	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—ERBB2—uterine cancer	4.5e-06	0.000187	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CXCL8—uterine cancer	4.27e-06	0.000177	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—HRAS—uterine cancer	4.24e-06	0.000176	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CDKN1B—uterine cancer	4.17e-06	0.000173	CbGpPWpGaD
Amantadine—DRD2—GPCR downstream signaling—AKT1—uterine cancer	4.12e-06	0.000171	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—CTNNB1—uterine cancer	3.94e-06	0.000164	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PTEN—uterine cancer	3.84e-06	0.000159	CbGpPWpGaD
Amantadine—DRD2—Signaling by GPCR—AKT1—uterine cancer	3.75e-06	0.000156	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—PIK3CA—uterine cancer	3.67e-06	0.000152	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—EP300—uterine cancer	3.66e-06	0.000152	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—VEGFA—uterine cancer	3.47e-06	0.000144	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—NRAS—uterine cancer	3.43e-06	0.000142	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—PIK3CA—uterine cancer	3.42e-06	0.000142	CbGpPWpGaD
Amantadine—SLC22A2—Metabolism—AKT1—uterine cancer	3e-06	0.000124	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—KRAS—uterine cancer	2.95e-06	0.000122	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PTEN—uterine cancer	2.84e-06	0.000118	CbGpPWpGaD
Amantadine—SLC22A1—Metabolism—AKT1—uterine cancer	2.79e-06	0.000116	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—EP300—uterine cancer	2.71e-06	0.000113	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—PIK3CA—uterine cancer	2.71e-06	0.000112	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—TP53—uterine cancer	2.62e-06	0.000109	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—HRAS—uterine cancer	2.51e-06	0.000104	CbGpPWpGaD
Amantadine—DRD2—Signaling Pathways—AKT1—uterine cancer	2.21e-06	9.19e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—PIK3CA—uterine cancer	2e-06	8.33e-05	CbGpPWpGaD
Amantadine—ABCB1—Metabolism—AKT1—uterine cancer	1.64e-06	6.8e-05	CbGpPWpGaD
